2273. Azithromycin Use Before and During COVID- 19 and Impact of Implementing Evidence-based Guidelines

por Shams, Sherin, Nafady-Hego, Hanaa, Thomas, Anil G, Saleem, Samah, Hanana, Fathima, Malik, Aimon, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Umar, Aftab Mohammad, Alkhal, Abdullatif, Almaslamani, Muna, Abou-Samra, Abdul-Badi, Butt, Adeel A
Publicado 2023

Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination

por Butt, Adeel A., Nafady-Hego, Hanaa, Chemaitelly, Hiam, Abou-Samra, Abdul-Badi, Khal, Abdullatif Al, Coyle, Peter V., Kanaani, Zeina Al, Kaleeckal, Anvar H., Latif, Ali Nizar, Masalmani, Yousuf Al, Bertollini, Roberto, Raddad, Laith J. Abu
Publicado 2021

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar

por Tayar, Elias, Abdeen, Sami, Abed Alah, Muna, Chemaitelly, Hiam, Bougmiza, Iheb, Ayoub, Houssein H., Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Al-Romaihi, Hamad Eid, Al-Thani, Mohamed H., Bertollini, Roberto, Abu-Raddad, Laith J., Al-Khal, Abdullatif
Publicado 2023

All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic

por AlNuaimi, Asma A, Chemaitelly, Hiam, Semaan, Sandy, AlMukdad, Sawsan, Al-Kanaani, Zaina, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Al-Romaihi, Hamad Eid, Butt, Adeel A, Al-Thani, Mohamed H, Bertollini, Roberto, AbdulMalik, Mariam, Al-Khal, Abdullatif, Abu-Raddad, Laith J
Publicado 2023

Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers

por Alishaq, Moza, Nafady-Hego, Hanaa, Jeremijenko, Andrew, Al Ajmi, Jameela Ali, Elgendy, Mohamed, Vinoy, Suni, Fareh, Sameera Bihi, Veronica Plaatjies, Justine, Nooh, Mariam, Alanzi, Nadya, Kaleeckal, Anvar H., Latif, Ali Nizar, Coyle, Peter, Elgendy, Hamed, Abou-Samra, Abdul-Badi, Butt, Adeel Ajwad
Publicado 2021

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar

por Zaqout, Ahmed, Almaslamani, Muna A., Chemaitelly, Hiam, Hashim, Samar A., Ittaman, Ajithkumar, Alimam, Abeir, Rustom, Fatma, Daghfal, Joanne, Abukhattab, Mohammed, AlMukdad, Sawsan, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Butt, Adeel A., Bertollini, Roberto, Al-Khal, Abdullatif, Omrani, Ali S., Abu-Raddad, Laith J.
Publicado 2022

COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar

por Butt, Adeel A, Dargham, Soha R, Tang, Patrick, Chemaitelly, Hiam, Hasan, Mohammad R, Coyle, Peter V, Kaleeckal, Anvar H, Latif, Ali Nizar, Loka, Srusvin, Shaik, Riyazuddin M, Zaqout, Ahmed, Almaslamani, Muna A, Al Khal, Abdullatif, Bertollini, Roberto, Abou-Samra, Abdul-Badi, Abu-Raddad, Laith J
Publicado 2022

Immediate and contributory causes of death in patients hospitalized with COVID-19

por Butt, Adeel A., Guerrero, Mylai D., Canlas, Elenor B., Al-Dwairi, Husni, Alzibdeh, Aseel Hatem Subhi, Odaippurath, Thasneem, Alkeldi, Ali Ahmed Sheikh Saleh, Mohammad, Mohammad Fawaz Saber, Thomas, Anil G., Shams, Sherin, Saleem, Samah, Hanana, Fathima, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Al-Khal, Abdullatif, Al-Maslamani, Muna, Abou-Samra, Abdul-Badi
Publicado 2023

Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19

por Ayoub, Houssein H, Chemaitelly, Hiam, Seedat, Shaheen, Makhoul, Monia, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A, Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Rahim, Hanan Abdul, Yassine, Hadi M, Al Kuwari, Mohamed G, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Bertollini, Roberto, Abu Raddad, Laith J
Publicado 2021

SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar

por Seedat, Shaheen, Chemaitelly, Hiam, Ayoub, Houssein H., Makhoul, Monia, Mumtaz, Ghina R., Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A., Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Yassine, Hadi M., Al Kuwari, Mohamed G., Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Bertollini, Roberto, Abu-Raddad, Laith J.
Publicado 2021

COVID-19 risk score as a public health tool to guide targeted testing: A demonstration study in Qatar

por Abu-Raddad, Laith J., Dargham, Soha, Chemaitelly, Hiam, Coyle, Peter, Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed G., Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Publicado 2022

Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months

por Abu-Raddad, Laith J., Chemaitelly, Hiam, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A., Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Yassine, Hadi M., Al Kuwari, Mohamed G., Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Bertollini, Roberto
Publicado 2021

Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease

por Bansal, Devendra, Abdulmajeed, Jazeel, Al-Shamali, Maha H. M. A., Albayat, Soha S. A., Himatt, Sayed M., Cyprian, Farhan S., Chivese, Tawanda, Mundodan, Jesha M. A., Khogali, Hayat S., Baaboura, Rekayahouda, Kaleeckal, Anvar H., Kandy, Mujeeb C., Latif, Ali Nizar, Al-Kuwari, Mohamed Ghaith, Al-Romaihi, Hamad Eid, Al Khal, Abdullatif, Bertollini, Roberto, Al-Thani, Mohamed Hamad, Farag, Elmobashar, Doi, Suhail A. R.
Publicado 2022

Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting

por Abu-Raddad, Laith J, Chemaitelly, Hiam, Malek, Joel A, Ahmed, Ayeda A, Mohamoud, Yasmin A, Younuskunju, Shameem, Ayoub, Houssein H, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A, Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F, Yassine, Hadi M, Al Kuwari, Mohamed G, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Bertollini, Roberto
Publicado 2020

SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study

por Mahmoud, Mai A., Ayoub, Houssein H., Coyle, Peter, Tang, Patrick, Hasan, Mohammad R., Yassine, Hadi M., Al Thani, Asmaa A., Al‐Kanaani, Zaina, Al‐Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul‐Rahim, Hanan F., Nasrallah, Gheyath K., Al‐Kuwari, Mohamed Ghaith, Butt, Adeel A., Al‐Romaihi, Hamad Eid, Al‐Thani, Mohamed H., Al‐Khal, Abdullatif, Bertollini, Roberto, Abu‐Raddad, Laith J., Chemaitelly, Hiam
Publicado 2023

Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic

por Abu-Raddad, Laith J., Chemaitelly, Hiam, Ayoub, Houssein H., Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Butt, Adeel A., Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Owen, Robert C., Rahim, Hanan F. Abdul, Al Abdulla, Samya A., Al Kuwari, Mohamed G., Kandy, Mujeeb C., Saeb, Hatoun, Ahmed, Shazia Nadeem N., Al Romaihi, Hamad Eid, Bansal, Devendra, Dalton, Louise, Al-Thani, Mohamed H., Bertollini, Roberto
Publicado 2021

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

por Abu-Raddad, Laith J., Chemaitelly, Hiam, Coyle, Peter, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Ayoub, Houssein H., Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Publicado 2021

Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population

por Nasrallah, Gheyath K., Dargham, Soha R., Shurrab, Farah, Al-Sadeq, Duaa W., Al-Jighefee, Hadeel, Chemaitelly, Hiam, Al Kanaani, Zaina, Al Khal, Abdullatif, Al Kuwari, Einas, Coyle, Peter, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Rahim, Hanan F. Abdul, Yassine, Hadi M., Al Kuwari, Mohamed G., Qotba, Hamda, Al Romaihi, Hamad Eid, Tang, Patrick, Bertollini, Roberto, Al-Thani, Mohamed H., Althani, Asmaa A., Abu-Raddad, Laith J.
Publicado 2021

Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses

por Abu-Raddad, Laith J, Chemaitelly, Hiam, Yassine, Hadi M, Benslimane, Fatiha M, Al Khatib, Hebah A, Tang, Patrick, Malek, Joel A, Coyle, Peter, Ayoub, Houssein H, Al Kanaani, Zaina, Al Kuwari, Einas, Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F, Nasrallah, Gheyath K, Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H, Al Khal, Abdullatif, Butt, Adeel A, Bertollini, Roberto
Publicado 2021

Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study

por Abu-Raddad, Laith J., Chemaitelly, Hiam, Ayoub, Houssein H., Coyle, Peter, Malek, Joel A., Ahmed, Ayeda A., Mohamoud, Yasmin A., Younuskunju, Shameem, Tang, Patrick, Al Kanaani, Zaina, Al Kuwari, Einas, Butt, Adeel A., Jeremijenko, Andrew, Kaleeckal, Anvar Hassan, Latif, Ali Nizar, Shaik, Riyazuddin Mohammad, Abdul Rahim, Hanan F., Nasrallah, Gheyath K., Yassine, Hadi M., Al Kuwari, Mohamed Ghaith, Al Romaihi, Hamad Eid, Al-Thani, Mohamed H., Al Khal, Abdullatif, Bertollini, Roberto
Publicado 2021